(File photo) Wu Xun. Figure/New
Wu Hun: "Vaccine Tsar" folded
China News Weekly reporter / Zhou Qunfeng
This article was first published in China News Weekly, Issue 869
2018 is wu xun's original life year. This year, he stepped into the flower armor.
On August 16, seven provincial and ministerial-level officials were held accountable by the central government for the Changchun Changsheng vaccine case: Jin Yuhui, vice governor of Jilin Province, and Li Jinxiu, vice chairman of the Jilin Provincial Committee of the Chinese People's Political Consultative Conference, were dismissed from their posts, ordered to resign, resigned, and deeply inspected. Wu Hun, former deputy director of the Food and Drug Administration, was filed for review and investigation.
On the same day, the official website of the Central Commission for Discipline Inspection and the State Supervision Commission released a message saying that Wu Hun was "suspected of serious violations of discipline and law" and was undergoing disciplinary review and supervision and investigation. He also became the first provincial and ministerial-level official to be examined and investigated for the Changchun Changsheng vaccine incident.
Wu Hun has served in the food and drug regulatory system for a long time, in charge of medicinal registration management, medicinal chemical supervision and audit inspection, etc., holding heavy powers. The vaccine industry is also under his control, and he is therefore known as the "Vaccine Czar" in the industry.
During the period when Wu Hun was in charge of vaccines, major domestic vaccine cases occurred frequently, which disgraced the reputation of domestic vaccines. In addition, he has become the protagonist of many real-name reporting incidents.
After Wu Hun's downfall, several officials of the Food and Drug Administration were dismissed from their posts, and his old subordinate Wang Lifeng, former director of the Department of Drug and Cosmetics Registration and Administration of the State Food and Drug Administration, was investigated. In 2017, another of his old subordinates, Yin Hongzhang, deputy director of the Drug Evaluation Center of the State Food and Drug Administration, was sentenced to 10 years in prison for accepting bribes.
In the context of drug reform, China's food and drug regulatory system has exploded a number of cases of violations of discipline and law typical of the Wu Hun case, which has also made more people in the industry think about how to standardize the system and where to go next in the drug reform.
Abnormal promotions
Nanfeng County belongs to Fuzhou City, Jiangxi Province, is a famous historical and cultural city in Jiangxi Province, and is also the hometown of Zeng Gong, one of the eight great masters of the Tang and Song Dynasties.
Public resumes show that Wu Hun was born in the county in May 1958. He started his career in August 1975 and graduated from jiangxi college of traditional Chinese medicine in 1983, majoring in traditional Chinese medicine.
Wu Hun worked for a long time in the health system of Jiangxi Province. He was a cadre of the Medical Education and Science and Technology Department of the Jiangxi Provincial Health Department, and from 1989 to 2000, he served as the deputy director and director of the Pharmaceutical Administration Bureau of the Jiangxi Provincial Health Department.
An insider in the medical industry told China News Weekly that when Wu Huan worked in Jiangxi, he was reported for "extending his hand too long." "After two years of silence, it is abnormally climbing higher and higher."
In the mid-to-late 1990s, the insider worked in the Jiangxi office of a pharmaceutical company in Sichuan for four years, serving as a provincial manager. A certain drug it represents occupies most of the market of Nanchang Hospital.
To his surprise, in 1997, the products of a pharmaceutical factory in Dalian occupied the Nanchang market almost overnight. "It blew my mind, it was incredible."
He said that in the field of drug agency, if similar products firmly occupy a hospital in a certain place, other drugs are coming, and it is usually a small fight, and it is difficult to turn over a big wave.
The insider began to investigate. He found that the sales boss of the pharmaceutical factory in Dalian had asked Wu Hun to "take care of it.".
At that time, the drugs belonged to the management of the health department, and Wu Hun was the director of the Drug Administration Bureau of the Jiangxi Provincial Health Department at that time. "The bureau directly administers all hospital medicines. For Wu Hun, using the power in his hands to intervene in the entry of drugs into Jiangxi Hospital is a breeze. ”
The insider also said that through his multi-party investigation, it was found that Wu Hun was not the first time to do such a thing. Previously, Wu Hun also cared for a pharmaceutical company in Taizhou, Jiangsu Province, and also had close contacts with several enterprises in the northeast.
"Wu Hun held a lot of power at that time, and he was not yet forty years old, and his future was immeasurable, and many hospitals did not dare not listen to him."
Soon, he anonymously reported Wu Hun's meddling in the sales of pharmaceutical companies to the Jiangxi Provincial Health Department and the Jiangxi Provincial People's Government.
The insider said that two or three months after his report, a certain type of drug from the pharmaceutical factory in Dalian completely withdrew from the Nanchang market, and "our company's products once again accounted for most of the market share."
The insider told China News Weekly that the relevant departments did not deal with Wu Hun publicly at that time, but in the more than two years since then, Wu Hun has become very low-key.
In 2000, the state and various provinces and cities established the Drug Administration, and Wu Hun served as deputy secretary and deputy director of the party group of the Jiangxi Provincial Drug Regulatory Bureau, and later as the secretary and director of the party group, and later as the director of the Jiangxi Provincial Food and Drug Administration and the secretary of the party group.
In September 2006, Wu Hun left Jiangxi, where he had worked for a long time, to Beijing to serve as the deputy director of the State Food and Drug Administration and a member of the party group, in charge of drug registration, supervision, review, vaccine industry and other work.
The above-mentioned insiders said that after Wu Hun was transferred to Beijing, he became a hot real power faction. "Logically, a person with a stain should not be promoted and reused."
Wu Hun's hometown of Feng County, Southwest Jiangxi, is known as the hometown of honey oranges, and has been paying tribute to the imperial family since the Tang Dynasty. An insider close to the national drug regulatory system told China News Weekly that Wu Hun is not only greedy, but also shoots. When he was working in Jiangxi, he took advantage of his position and in the name of welfare to deliver honey oranges to the State Food and Drug Administration and the China Food and Drug Inspection institute every year.
Just over 3 months after Wu Hun went to Beijing, the State Food and Drug Administration broke out into heavy news. On December 26, 2006, Zheng Xiaoyun, then director of the bureau, was "shuanggui" by the Central Commission for Discipline Inspection.
On May 29, 2007, the Beijing Municipal No. 1 Intermediate People's Court rendered a first-instance judgment in the Case of Zheng Xiaoyun, sentencing Zheng Xiaoyun to death for accepting bribes, depriving him of his political rights for life, and confiscating all his personal property; sentenced him to 7 years' imprisonment for dereliction of duty, punishing him for both crimes, and deciding to carry out the death penalty, depriving him of his political rights for life, and confiscating all personal property. On June 22, a second-instance ruling was rendered, rejecting the appeal and upholding the original judgment. On July 10, Zheng Xiaoyun was executed.
Zheng Xiaoyun, then 62 years old, lamented in the "Testament of Remorse" left before being executed: "Tomorrow I will be 'on the road', and what I am most afraid of now is how will I face the unjust souls who were killed by me?" I pray that they will forgive me, forgive me, and don't I already have retribution? ”
It is worth noting that Wu Hun's name also appeared in Zheng's verdict. In accordance with Zheng Xiaoyun's instructions, Wu Hun accepted the request of a company in Guangdong to do things for the company.
Zheng Xiaoyun's first-instance judgment shows that the testimony of witness Zhao Xiaoming (then director of the Drug Market Supervision Department of the State Food and Drug Administration) proves that in August 2000, Zheng Xiaoyun asked him to support a company in Guangdong to apply for a drug retail inter-provincial chain operation, and the application was approved. In 2003, the State Food and Drug Administration's drug license management measures have not yet been introduced, the company's drug logistics distribution center "drug business license" can not be processed for the time being, when Zheng Xiaoyun inspected the logistics distribution center, the company's person in charge of the matter to Zheng Xiaoyun for this matter to ask Zheng Xiaoyun for support. Zheng Xiaoyun instructed Wu Xun, director of the Jiangxi Provincial Bureau, to ask the State Bureau for instructions, and the State Bureau approved the solution of the problem. Later, Wu Hun approved and agreed to handle it according to Zheng Xiaoyun's instructions.
After Zheng Xiaoyun fell, Wu Hun repeatedly stated publicly, saying that he could not deny the entire drug regulatory system because of Zheng Xiaoyun.
In February 2007, Wu Hun said when he was a guest of the Chinese government website: "I would like to say here that although there have been corruption cases in our drug regulatory system like Zheng Xiaoyun, Cao Wenzhuang and others, we cannot deny the team of drug supervision because of the problems of a few people, nor can we deny the work and achievements made by the drug regulatory system over the years, nor can we shake our confidence in doing a good job in supervision and guarding for the people." ”
In December of the same year, at a press conference held by the State Council's new office, Wu Hun said, "Zheng Xiaoyun has been severely punished by the law, and the results have been reported in the news, and I think everyone already knows." Zheng Xiaoyun's corruption case has had some negative impact on the drug regulatory system, which has humiliated our drug regulators, and we are sad about it. ”
He also said that a system and a team cannot be denied because of a person's problems. "I am very confident to tell you that this team of China's food and drug supervision is good, this team can afford to suffer, dare to touch the hard, and is a team with combat effectiveness."
After the Zheng case, Wu Hun was not affected.
Since April 2013, Wu Hun has served as a member of the Party Group of the State Food and Drug Administration, the director of food and drug safety, the deputy director of the State Food and Drug Administration, a member of the party group, and the deputy director of the National Health and Family Planning Commission.
In March 2018, in a new round of government agency reform, the State Food and Drug Administration was abolished and the State Food and Drug Administration was established separately, which was managed by the State Administration for Market Regulation.
Wu Huan, who is less than 60 years old, did not serve in the State Administration for Market Regulation, and his whereabouts were not officially announced.
Five months later, he was ousted due to the elixir vaccine incident and once again became the focus of public opinion.
Wu Hun, then deputy director of the State Food and Drug Administration, served as the secretary general of the State Pharmacopoeia Commission from August 2007 to June 2011. A retired official of the State Pharmacopoeia Commission summed up his impression of Wu Hun in terms of "self-indulgence, insatiable greed, and two gains in wealth."
But for the specifics, the retired official told China News Weekly that Wu Hun had been rewarded and did not want to say anything more. "If he's not unlucky, I'd like to talk about it."
Twice reported under his real name
During wu hun's more than ten years in charge of the vaccine industry, major vaccine cases such as the Shanxi vaccine case and the Jiangsu Yanshen vaccine case occurred frequently. Due to the vaccine problem incident, he was reported by his real name twice during his term of office.
On August 18, 2014, Ma Wenfang, a deputy to the National People's Congress and a village doctor in Henan, and Zhang Yi, a deputy to the Henan Provincial People's Congress and chairman of Henan Yisheng Pharmaceutical, jointly reported Wu Hun, Yin Hongzhang (then deputy director of the Drug Review Center of the State Food and Drug Administration) and Shen Qi (director of the Biological Products Verification Institute of the China Academy of Food and Drug Control), calling them "dereliction of duty, abuse of power, and suspected dereliction of duty." They called the report "a removal of artificial barriers to national scientific and technological innovation."
According to the whistleblower letter, Zhang Yi repeatedly reported to Wu Hun about the problems of his subordinate Yin Hongzhang. In 2006, when Yin Hongzhang was the director of the Biological Products Division of the Drug Registration Department of the State Food and Drug Administration, he illegally returned the world-leading innovative drugs that Zhang's company, Yisheng Pharmaceutical, had been recognized by the evaluation center to enter clinical trials; in 2010, Yin Hongzhang was transferred to the deputy director of the Drug Evaluation Center, "using the power in his hands to dominate the review work after the drug, so that the innovative drugs that should have entered the clinical trial failed to pass the review again."
Zhang Yi also said that he declared 25 batches of rabies vaccine batches for issuance, and for 5 years he did not get any reply, and could only watch the vaccine worth about 30 million yuan be destroyed after expiration. The 117 batches of qualified vaccines declared from 2012 to 2013 also caused a loss of nearly 400 million yuan due to the problem of batch issuance.
Zhang Yiyi said that as the direct leader of Yin Hongzhang, Wu Hun deliberately covered up Yin Hongzhang's behavior and did not investigate.
According to the Central Broadcasting Network Economic Voice "Tianxia Finance", Zhang Yi found Wu Hun and said that his company had been unfairly treated in the drug review, hoping that the State Food and Drug Administration would re-examine its vaccine, but Wu Hun refused.
Wu Hun said to Zhang Yi, "You don't understand business. This review is worthless. Zhang Yi, who came from the epidemic prevention station, insisted that he understood business. Wu Xun actually exploded and said, "You know a fart!" ”
In April 2015, Yin Hongzhang was detained and summoned on suspicion of accepting bribes and arrested in August of the same year.
In March 2016, Shandong police cracked a case of illegal vaccines worth 570 million yuan, which were sold to 24 provinces and cities without strict cold chain storage and transportation, shocking the whole country.
The illegal vaccine operation in Shandong continued to ferment during the Boao Forum for Asia. At the Boao Forum for Asia 'Reform of the Drug Review and Approval System', Wu Hun had to face the problem of vaccine supervision.
In the face of the media's pursuit and interception, Wu Hun said that there are indeed loopholes in the circulation process of Shandong vaccines, vaccines are preventive products, and will not cause physical harm to healthy people who are injected.
"After verification, the violations of laws and regulations and criminals in the vaccine business will be severely punished, whether it is units, individuals, enterprises or institutions, where to deal with where and who is involved." He said.
"Do you think vaccines are safe?" A reporter asked. Wu Hun replied: "If this question is something I can answer by saying yes or no, then the forum can be ended immediately." ”
Wu Hun also said that the products involved in the case are basically the products of regular enterprises. The core problem of the vaccine involved in the case is that it is out of the cold chain during transportation and storage, which will cause the vaccine to be less effective, that is, it will not achieve the effect of preventing diseases. "Whether there is harm to the human body after the vaccine fails, this is a scientific question, which needs to be answered by scientists, not simply with a few words to pat the head can answer, to use data to speak."
A reporter from the China Business Network at the time described Wu Hun's embarrassment as follows: After the forum, the media reporters surrounded Wu Hun from the forum conference hall to the security checkpoint of the venue hotel, and Wu's entourage refused to be interviewed on the grounds that "Wu Hun has other activities". Finally, Wu was escorted from the security checkpoint by his entourage.
At the end of the same year, another real-name reporting incident once again pushed Wu Hun to the cusp of public opinion.
In November 2016, Du Taoxin, then a reporter for Democracy and The Law Times, reported Wu Hun under his real name, accusing him of abusing his power, dereliction of duty, and dereliction of duty while he was in charge of vaccines, and had an unshirkable responsibility.
The whistleblower letter listed a number of problems such as Wu Hun's failure to recall the vaccines involved in accordance with the law, resulting in a continued increase in deaths.
According to the whistleblower letter, in March 2009, the China Pharmaceutical and Biological Products Laboratory under the State Food and Drug Administration found that there was a problem with the rabies vaccine produced by two enterprises in Yanshen, Jiangsu province and Hebei Fore, and Wu Hun not only failed to take timely recall measures, but also concealed it until December 2009. During the period of concealment, Wu Hun also "stood" for Jiangsu Yanshen.
From September 16 to 17, 2009, the symposium on the supervision of the production of influenza A vaccine was held in Changzhou, and Wu Hun personally led the personnel of the China Pharmaceutical and Biological Products Laboratory to attend. At this meeting, Jiangsu Yanshen received 1.6 million orders for A flow, with a planned total production of 16.6 million doses. On September 18, Jiangsu Yanshen obtained the GMP certificate for the production of influenza A vaccine.
On September 26, 2009, Yangtze Evening News and other media reported that Wu Hun had made a special trip to Jiangsu Yanshen Company to inspect and guide the production of A-stream, helping the company to successfully complete research and development, production and other work.
According to the whistleblower letter, the Jiangsu Yanshen crazy seedling incident was not only not announced, recalled and held accountable, but also obtained orders for A-stream vaccines worth more than 100 million yuan. In May and November 2009, Jiangsu Yanshen successfully transferred 50.77% of its shares to Simcere Pharmaceutical.
The whistleblower letter also said that since November 2013, there have been four suspected deaths after receiving Kangtai recombinant hepatitis B vaccine in Guangdong Province, with a cumulative total of 7 cases nationwide. At that time, Wu Hun did not recall the vaccines involved in the case in a timely manner in accordance with the law, resulting in a continuous increase in death cases. After the CCTV exposure on December 13 of the same year, on December 20, the Food and Drug Administration and the Health and Family Planning Commission issued a notice to suspend the vaccines involved.
Du Taoxin also questioned whether the frequent occurrence of major cases such as the Shanxi vaccine case, the Jiangsu Yanshen, Hebei Fowl rabies vaccine case, the 2013 hepatitis B vaccine case, the 2016 Shandong vaccine case, and the reputation of domestic vaccines suffered heavy damage were all related to Wu Hun's slackness. Wu Hun was also involved in other violations of law and discipline such as bending the law for personal gain and abusing his power. I am in the process of further sorting out. ”
Before reporting under his real name in his personal name, Du Taoxin had written an article exposing the vaccine chaos. In 2014, he published a report in democracy and the Legal Times in a report titled "Food and Drug Administration Officials Caught in 'Whistleblower' Vaccine Case," exposing the chaos in China's vaccine market. The report said that the Food and Drug Administration had planned a batch issuance system, and Wu Hun used double standards. The report also revealed that Du Weimin, chairman of Shenzhen Kangtai Biological Products Co., Ltd., controlled Jiangsu Yanshen shares cashed out 200 million.
After the report was issued, Du Weimin sued Du Taoxin for defamation infringement. In the end, the court ruled that Du Taoxin lost the lawsuit and the reputation infringement was established.
It is worth mentioning that Du Weimin was a fellow of Wu Hun's Jiangxi province, and he had paid bribes to Yin Hongzhang, a subordinate of Wu Hun.
In 2017, Yin Hongzhang, deputy director of the Drug Evaluation Center of the State Food and Drug Administration, was sentenced to 10 years in prison for accepting bribes, along with his wife and son. The court found that between 2002 and 2014, the Yin family of three received a total of more than 3.56 million yuan in property from a number of biopharmaceutical companies.
China News Weekly learned from the criminal verdict of the first instance trial of Yin Hongzhang's bribery that Du Weimin had paid a bribe of 470,000 yuan to Yin Hongzhang. The verdict said that in 2010, Yin Hongzhang and Du Weimin met. At that time, Yin Hongzhang served as the deputy director of the Drug Evaluation Center of the State Food and Drug Administration, in charge of the technical review of biological products. In early 2011, Yin Hongzhang bought a small property villa, and he found that Du Weimin also lived in the same neighborhood, so he gradually became closer.
Du Weimin's testimony proved that in order to let Yin not embarrass his company in terms of approval, he twice sent Yin a total of 470,000 yuan. One day in 2011, he and Yin Hongzhang, Guo × Jia were all guests at the neighbor's house, and when Yin Hongzhang and Guo × Jia returned home, Du asked the driver Mao × to send them home, and by the way, Let Mao × give Yin Hongzhang a bag containing 170,000 yuan in cash.
In the second half of 2011, Du once had dinner with Yin Hongzhang, and after the meal, Mao × sent him and Yin Hongzhang home. In the car, Du said to Yin Hongzhang: "Director Yin, here is a bag, which contains a little gift I prepared for you, and you take it when you get out of the car." Yin Hongzhang was polite for a moment and accepted it. The bag contained $300,000 in cash.
China News Weekly learned that Guo × Jia in the verdict was Yin Hongzhang's wife.
According to public reports, Du Weimin is a fellow of Wu Hun's Jiangxi Province, an inspector in the inspection department of the Jiangxi Provincial Health and Epidemic Prevention Station in his early years, and in 1993, he and Han Gangjun, who had served as a deputy station chief at the Longting District Health and Epidemic Prevention Station in Kaifeng, Henan Province, went to the sea to enter the vaccine industry.
In 2001, Du Weimin served as the sales director of Changsheng Biotech and joined hands with Han Gangjun to become a minority shareholder of Changsheng Biotech. An insider told China News Weekly that during the tenure of Du Weimin and Han Gangjun in Changsheng, Gao Junfang, the boss of Changsheng, left a vaccine workshop for the two to contract.
According to the data, in 2007, Han and Du went south and took 90% of the shares of Changzhou Yanshen for 20 million yuan, which was transformed into Jiangsu Yanshen, with Han Gangjun as the chairman. Two years later, Yanshen Bio was punished the following year in the case of a fake and shoddy rabies vaccine, the general manager was sentenced, and the chairman Han Gangjun was unharmed.
Before the Yanshen vaccine case, Du Weimin had moved to Shenzhen and became the actual controller of Kangtai Biological Products Co., Ltd.
Du Weimin and Wu Hun were fellow Jiangxi villagers who started out in the Jiangxi health system and were bribe-givers to Wu's subordinate Yin Hongzhang. Whether there is a relationship of interest transmission with Wu Hun has yet to be officially disclosed.
Many subordinates were investigated
A lawyer who represented many cases in the field of food and medicine told China News Weekly that Wu Hun, a subordinate of the former State Food and Drug Administration, once commented on Wu: "He has a deep understanding of domestic supervision, is good at summarizing, is good at grasping the main points, has ideas, hopes to manage drugs well, sometimes too strictly, engage in sports-style supervision, and the effect is not obvious." ”
After Wu Hun's august 16 sunset, several officials of the Food and Drug Administration system were held accountable.
On August 18, the official website of the State Food and Drug Administration published a message entitled "State Administration of Market Supervision and Administration Accountability for Staff Related to Problem Vaccine Cases", saying that the Changsheng problem vaccine case exposed many loopholes such as the lack of supervision of the relevant staff of the former State Food and Drug Administration and the State Drug Administration, weak supervision and guidance, lax review and control, and negligence.
The article revealed that after the study and decision of the party group meeting of the State Administration for Market Supervision and Administration, 6 officials were dismissed.
Among the 6 people, in addition to Wang Youchun, vice president of the China Institute of Food and Drug Control, the remaining 5 are from the former State Food and Drug Administration (STATE FOOD AND DRUG Administration) Department of Drug and Cosmetics Supervision, namely Director Ding Jianhua, Deputy Director Dong Runsheng, Deputy Director General Sun Jinglin, Director General Ye Guoqing, and Special Drug Supervision Division Researcher Guo Xiuxia.
The Department of Drug and Cosmetics Supervision and the China Institute of Food and Drug Control are both areas under wu's responsibility.
On the evening of August 23, the official website of the State Administration for Market Regulation released the news that Wang Lifeng, former director of the Department of Drug and Cosmetics Registration and Administration of the State Food and Drug Administration (Department of Supervision of Traditional Chinese Medicines and Ethnic Drugs), was suspected of serious violations of discipline and laws and is currently under disciplinary review and supervision and investigation.
Wang Lifeng is An old subordinate of Wu, who has worked with Wu Hun for many years, and the two have promoted the reform of the drug review and approval system together, and have attended many events together.
On June 22, 2018, at the State Council's regular policy briefing, Wang Lifeng and Jiao Hong, director of the State Drug Administration, jointly introduced the work related to accelerating the review and approval of new drugs listed overseas. This was Wang Lifeng's last public appearance.
The Department of Drug and Cosmetics Registration and Administration is mainly responsible for optimizing the management process of drug and cosmetics registration and administrative licensing, as well as undertaking the evaluation of vaccine regulatory quality management system and the administrative protection of drugs.
The department is one of the core departments of the former Food and Drug Administration, formerly known as the Drug Registration Department of the former State Food and Drug Administration. In 2006, Cao Wenzhuang, then director of the department, was investigated. The case was called "the first case of commercial bribery in the country" by the China Procuratorial Publishing House, "Let Corrupt Officials Speak." The division is also known as the "world's first division" because it controls the registration of drugs in thousands of pharmaceutical factories across the country.
"Let corrupt officials open their mouths" recorded a passage from Zhang Jingwen, then director of the Anti-Corruption and Bribery Bureau of the People's Procuratorate of Xicheng District, Beijing, saying, "At that time, we felt that more than 3,000 pharmaceutical factories were completely controlled by the Registrar. ”
The Drug Review Center is responsible for the technical review of the drug, and based on the review opinions, the Drug Registry decides whether to register it.
A medical industry practitioner told China News Weekly that because the department's authority is too large, the department's officials are also easy to become the object of "hunting" by enterprises, and before Wu Hun was in power, the department had frequent problems and frequent violations of discipline and law.
Wang Lifeng previously served as the director of the Inspection Bureau of the former State Food and Drug Administration and the secretary general of the Pharmacopoeia Committee. On June 5, 2013, he was appointed As the Director General of the Department of Registration and Administration of Drugs and Cosmetics (Department of Supervision of Traditional Chinese Medicines and Ethnic Medicines).
Wang Chenguang, director of the Health Law Research Center of Tsinghua University Law School, vice president of the China Health Law Society, and former legal adviser of the State Food and Drug Administration, said in an interview with China News Weekly that in the past three years, the achievements of the reform of the drug regulatory system have been affirmed by the industry, which has laid a good foundation for improving the ecological environment of the pharmaceutical industry. At the same time, it should be noted that these reforms mainly focus on the supervision of drug clinical trials and registration and listing. He said that the reform should be further extended to the whole life cycle supervision of drug production, operation and use.
"Only by grasping the scientific laws of drug research and development, production, circulation and use, and determining the status and responsibility of R&D, production, circulation and users and several departments according to law, can we continuously deepen the reform of the drug regulatory system, purify the ecological environment of the pharmaceutical industry, and ensure the accessibility and safety of people's medication." Wang Chenguang said.
Duty Editor: Yu Yang